June 22, 2015: WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited seven more organizations, one of the largest groups in recent memory.
Three of the newly accredited organizations are in Asia, a region that is leading the international community in embracing AAHRPP accreditation. In fact, more than 10 percent of AAHRPP-accredited organizations are located there.
The newly accredited organizations are:
According to AAHRPP President and CEO Elyse I. Summers, the group is significant for its size and composition, both of which highlight “the growing, global recognition of the value of AAHRPP accreditation and the need for one standard worldwide to protect research participants.”
The newly accredited organizations include four highly respected U.S. academic institutions, a top-ranked university in China, and two of Taiwan’s leading hospitals.
“With these accreditations, we take another important step in extending AAHRPP’s high standards and advancing high-quality, ethical research around the globe,” Summers said. “We applaud the newly accredited-and all AAHRPP-accredited-organizations for their commitment to excellence and, above all, to safeguarding research participants.”
To earn AAHRPP accreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. In today’s global, collaborative research enterprise, organizations increasingly rely on AAHRPP accreditation status to help identify trusted research partners.
To date, AAHRPP has accredited more than 210 organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and over 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process. The National Institutes of Health, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
###
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.